The World Health Organization (WHO) has approved the Covovax coronavirus vaccine for emergency use. It is produced by the Serum Institute of India under license from the American company Novavax.
The vaccine is part of the COVAX portfolio, which is driving ongoing efforts to vaccinate more people in low-income countries, the WHO said in a statement.
Earlier on Friday, the WHO announced the results of evaluating the effectiveness of vaccination against coronavirus with drugs created on the basis of different technologies. According to the organization’s experts, the effectiveness of vaccination or revaccination with viral vector drugs and drugs based on mRNA technology ranges from 61 to 91%. At the same time, vaccination only with drugs with mRNA technology on average can be 69-90%, and with vaccines with a platform of the viral vector of adenovirus – from 43 to 89%.
The introduction of a booster dose of the vaccine, which differs from the drug introduced during the first two vaccinations, also showed high efficiency.
Source: Rosbalt
Tristin is an accomplished author and journalist, known for his in-depth and engaging writing on sports. He currently works as a writer at 247 News Agency, where he has established himself as a respected voice in the sports industry.
